PP75. DROSOPHILA MELANOGASTER AS A MODEL ORGANISM TO STUDY GLIOMA: LOCATION AND IDENTIFICATION OF FOLLISTATIN

Abstract

Gliomas are the most common, malignant brain tumour found in the central nervous system. The main characteristics of gliomas is their rapid proliferation, resistance to current chemotherapies and their ability to infiltrate the brain. Brain tumours have a low survival rate due to the lack of available treatments. In the UK between 2010 and 2011, the survival rate was 14% for 10 or more year. The mortality rates for malignant brain and CNS tumours have increased by up to 24% in the UK between 1970 and 2012. As there is difficulty obtaining glioma samples, it is important to identify a suitable model organism. The main signalling pathways seen to be activated in human glioma development are the epithelial growth factor receptor (EGFR) and phosphatidylinositol-3 kinase (PI3K) pathways. The homologous EFGR and PI3K pathways have been studied greatly in drosophila, and show that there must be co-activation of the EGFR and PI3K pathways for cancer development to occur; leading to an increase in glial cell numbers by 50-100x fold. Follistatin is a protein which has been identified as a biomarker in malignant gliomas; by comparing normal serum to glioma serum it has shown that there is an overexpression of follistatin. Gliomas can be replicated in drosophila as there has been a high level of homology identified in human diseased states and in neural development. Follistatin studies have shown it has important roles in development and differentiation of tissues and organs. It acts as an inhibitor, binding to activin, bone morphogenetic proteins and other proteins which can be found in vertebrates. Follistatin has been identified within a number of different cancer types (such as prostate and ovarian), and plays an important role in cancer metastasis and angiogenesis. Serum studies have revealed follistatin is present in the early stages of cancer development; however the location and role of follistatin in cancer development has not been identified. Drosophila contain a homolog of follistatin, which will allow studies of follistatin in cancer within drosophila. By using drosophila as a model organism it will allow the location of follistatin and its involvement in glioma development to be identified. Immunohistochemistry is used to identify the location and distribution of a protein within a tissue or an organ. It is commonly used to identify which proteins are present in specific types of cancer. Follistatin has been identified to play a role in the early stages of glioma development. Therefore by using immunohistochemistry follistatin can be identified throughout the different stages of glioma development and possibly identify its role in this development. The aim of the research is to identify and locate the protein follistatin in drosophila by using immunohistochemistry. Using different larval instar stages, this will identify the distribution of follistatin in different stages of neural development. The hypothesis would be that follistatin is involved in the early stages of glial development and the distribution is important in glioma development compared to normal neural development.